A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Berzosertib (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 16 Jul 2019 Planned initiation date changed from 1 Jul 2019 to 2 Jan 2020.
- 15 Feb 2019 Planned initiation date changed from 1 Feb 2019 to 1 Jul 2019.
- 19 Jan 2019 Trial design presented at the 2019 Gastrointestinal Cancers Symposium